NCT07606066Recruiting
A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies
Source: ClinicalTrials.gov · Last updated 25 Aug 2026
Brief summary (registry, in English)
The purpose of this study is to identify and characterize patients with known Type 2 Diabetes Mellitus (T2DM) for possible participation in ongoing or future T2DM clinical studies, and to characterize trends in key concomitant medication use in this patient population across different geographical regions.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 2150 (estimated)
- First submitted
- 30 Apr 2026
- Start date
- 6 May 2026
- Primary completion date
- 31 Mar 2027
- Lead sponsor
- AstraZeneca
- Diseases
- Type 2 diabetes
- NCT number
- NCT07606066
What you commit to
- Study type: Observational
- Planned participants: 2150
- From 6 May 2026 to the primary completion date, 31 Mar 2027
- 66 sites in 7 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Diagnosed with Type 1 diabetes mellitus.
Other
- Current or planned use of GLP-1 RAs prohibited in ongoing or future T2DM studies evaluating the efficacy and safety of investigational GLP-1 RAs (As specified in the Protocol).
- Known pregnancy at the time of visit or having the intention to become pregnant.
Who the study is looking for
- Participants must be ≥ 18 years of age at the time of signing the ICF.
- Patients with a diagnosis of T2DM, test- or documentation-confirmed as per World
- Health Organization or local diagnostic standards, inadequately managed with:
- Lifestyle management alone, AND/OR
- A stable dose of background glucose-lowering medication(s) for T2DM (As specified in the Protocol) for at least 45 days prior to signing the ICF.
- Expresses interest in participating in an ongoing or future T2DM clinical study, is motivated and willing to make themselves available for the duration of the study, and is able to follow study procedures as required.
- Provision of signed and dated written informed consent (As specified in the Protocol) before any study-specific procedures, sampling, or analysis.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (66)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.